22.26
붉은털(Rh) 항원은 혈액형을 결정하고 수혈 중 호환성을 보장하는 데 중요합니다.
붉은털 항원 및 혈액형
Rh 항원은 대부분의 개인에서 적혈구(RBC) 표면에서 발견되는 단백질입니다. 그것의 유무는 사람의 혈액형을 Rh 양성 또는 Rh 음성으로 분류합니다. 예를 들어,…
붉은털 또는 Rh 항원은 적혈구 또는 적혈구에 있는 응집체의 한 종류입니다. 그것의 존재 또는 부재는 사람을 Rh 양성 또는 Rh 음성으로 분류합니다.
개인의 혈액형을 보고할 때 Rh 항원은 일반적으로 A 및 B 항원과 결합됩니다.
예를 들어, 항원 A와 Rh를 가진 사람의 혈액형은 A 양성으로 지정됩니다. 반대로, Rh 항원이 없는 경우 환자의 혈액은 A-음성이라고 합니다.
ABO 시스템과 달리 혈장에는 자연적으로 항-Rh 항체가 포함되어 있지 않습니다.
따라서 Rh 항원에 노출되면 Rh 음성 개인에서 면역 반응을 유발하여 용혈을 유발할 수 있습니다.
예를 들어, Rh 음성 어머니가 Rh 양성 태아를 낳았다고 가정합니다. 이 경우 산모의 면역체계는 태아 적혈구의 Rh 항원을 이물질로 인식하여 항-Rh 항체 생성을 유발합니다.
일반적으로 이러한 항체는 첫 임신을 방해하지 않는다. 그러나, Rh 양성 태아를 임신한 후의 경우, 태아 적혈구는 산모의 혈액 내에 존재하는 항-Rh 항체로 인해 용혈의 위험이 있습니다.
View the full transcript and gain access to JoVE Core videos
Q1: What is the Rh antigen and how does it determine blood type?
The Rh antigen is a protein on red blood cell surfaces that classifies blood as Rh-positive or Rh-negative. Its presence or absence is combined with ABO antigens to designate complete blood types, such as A-positive or B-negative. Understanding the Rh factor is essential in transfusion medicine for ensuring blood compatibility.
Q2: Why don't Rh-negative people naturally have anti-Rh antibodies?
Unlike the ABO system, plasma does not naturally contain anti-Rh antibodies. Anti-Rh antibodies develop only after exposure to the Rh antigen, triggering an immune response in Rh-negative individuals. This delayed response is why first transfusions with incompatible Rh blood may not cause immediate problems, but subsequent exposures carry greater risk.
Q3: How does Rh incompatibility affect pregnancy and the fetus?
When an Rh-negative mother carries an Rh-positive fetus, her immune system may recognize fetal Rh antigens as foreign, producing anti-Rh antibodies. In the first pregnancy, these antibodies typically cause no harm. However, in subsequent pregnancies with Rh-positive fetuses, existing antibodies cross the placenta and attack fetal red blood cells, causing hemolysis and hemolytic disease of the newborn.
Q4: What is RhoGAM and how does it prevent hemolytic disease of the newborn?
RhoGAM is a serum containing anti-Rh antibodies administered to Rh-negative mothers during and after delivery of Rh-positive babies. It prevents the mother's immune system from recognizing fetal Rh antigens as foreign, stopping anti-Rh antibody production. This protective measure significantly reduces the risk of hemolytic disease in future pregnancies.
Q5: How is the Rh blood group reported alongside the ABO system?
The Rh antigen status is combined with ABO antigens when reporting blood type. A person with A and Rh antigens is designated A-positive, while someone with A antigens but no Rh antigen is A-negative. This combined classification ensures accurate blood matching for transfusions and identifies potential maternal-fetal incompatibility risks.
Q6: What happens when Rh-negative individuals receive Rh-positive blood?
Exposure to Rh-positive blood triggers an immune response in Rh-negative individuals, leading to anti-Rh antibody production. This can cause hemolysis, the destruction of red blood cells, resulting in transfusion complications. Subsequent transfusions with Rh-positive blood carry increased risk of severe hemolytic reactions due to existing antibodies.
Q7: Why is understanding Rh compatibility critical in transfusion medicine?
Incompatible Rh factors between donor and recipient trigger immune responses causing hemolysis and potential life-threatening complications. Proper Rh typing prevents transfusion reactions and is especially vital for Rh-negative recipients who lack natural anti-Rh antibodies. Accurate Rh classification ensures safe blood matching and protects patient health during transfusions.